OBP-301 (Telomelysin)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OBP-301 (Telomelysin), covering 2023-01-11 to 2023-01-11. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease [Phase 2]